Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Metabolic disorders
Biotech
Zealand inks $1.2B Generate pact for anti-obesity protein R&D
Zealand Pharma is paying Generate Biomedicines $30 million upfront to collaborate on multispecific drug candidates for metabolic diseases.
Nick Paul Taylor
Oct 14, 2026 4:08am
After trimming headcount, Aardvark drops trials as wait drags on
Aug 12, 2026 9:03am
GSK pens $1B deal for metabolic oligonucleotide from SiranBio
May 6, 2026 8:04am
Aardvark halts obesity trials, putting entire pipeline on pause
Mar 24, 2026 4:00am
Aardvark pauses ph. 3 hunger trial over 'cardiac observations'
Mar 2, 2026 4:40am
OrsoBio hits target in midstage study for metabolic conditions
Feb 10, 2026 8:00am